James Chambers
@jchambers241
Followers
345
Following
743
Media
34
Statuses
400
Professor, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center
Boston, MA
Joined August 2017
What is the outlook for US payer coverage of specialty therapies in 2025? Expect more utilization management on pricey therapies. For more insights, register for CEVR's December 4 webinar led by @jchambers241 here: https://t.co/jVpCK6xMqw
0
1
4
Great overview of how the @TuftsCEVR SPEC database can inform discussions around emerging trends in specialty drug coverage. #amcpnexus2024 @jchambers241
2
1
3
Great poster at #amcpnexus 2024 from @Impacteduc on commercial health plan coverage of anti-VEGF therapies for retinal eye diseases. Plans included step therapy in 54% of coverage policies, most often through bevacizumab. @jchambers241
0
1
2
Join us in Las Vegas for #AMCPNexus 2024 for 2 educational sessions by @jchambers241 and @mollytoba's presentation of Fariel LaMountain's Platinum Ribbon-winning research on adalimumab product coverage. A full list of CEVR participation can be found here: https://t.co/U0dCpZdMn3
0
4
4
One month from today in Boston, the special symposium on cost-effectiveness analysis. Panel 2 of 5 panels is featured below. @socmdm. Join us!
The 2nd panel at 10/26 Tufts-CEVR / Duke Margolis symposium will feature reflections on CEA from three luminaries: @AnkurFactorial, Marthe Gold, and Charles Phelps. Register now: In Person: https://t.co/L5gA6C35ch Webinar: https://t.co/WsaGPFDEVY
0
2
9
Ultra-orphan drugs bring larger health benefits than orphan/non-orphan drugs, but tend to be less cost-effective. Read new research in @ISPORJournals from current/former CEVRs Clifford, @adelealexandr, Enright, @PeterNeumann11, and @jchambers241
https://t.co/e6hC9vfPPR
0
3
2
Does #biosimilar underutilization foretell a broken biologics market? CEVR’s LaMountain, @mollytoba, @jchambers241 and @genentech's Wong and Kim used #SPEC data to study 4 biologics w/ biosimilars. Read in @Health_Affairs scholar: https://t.co/FexAaKY8n6
#HAScholar
academic.oup.com
Abstract. Biosimilars offer the potential for cost savings and expanded access to biologic products; however, there are concerns regarding the rate of bios
1
4
5
In today’s @Health_Affairs Forefront, CEVR’s @adelealexandr, @jchambers241, and Genentech’s Stacey Kowal argue Medicare drug price negotiations should consider non-clinical benefits to patients/families as part of unmet need. #IRA #Pharma
https://t.co/Uq2ynHl0Qz
0
5
6
Are you passionate about health policy, evidence, and understanding the value of health care interventions? Apply to join CEVR as a Research Associate II today! https://t.co/o7Yu7EHyHI
#HEOR #Hiring
2
5
4
2. SPEC #DatabaseCoordinator: Maintain & grow the SPEC Database. Work closely with our research team to examine patient access to specialty therapies. https://t.co/iPIJlGIJ2b Apply now & be part of cutting-edge healthcare research!
0
3
5
Tufts-CEVR is #hiring for TWO positions: 1. SPEC #ResearchAssistant II: Support our research on health plan coverage of medical tech, health economics, & cost-effectiveness analyses. Strong writing & organizational skills needed.
1
5
6
We’ve updated the CEA Registry with new search and reporting tools for sponsors. Log in to see the impact of these advances! https://t.co/qQKc44WiM7
#CEA #HEOR #healtheconomics
0
2
2
Friday is the deadline. Submit your 46th Annual Meeting abstract for consideration today: https://t.co/iLVtWTBdKN
1
6
11
@mollytoba @TuftsCEVR @jchambers241 @PeterNeumann11 Thanks for the chat on this work. Great research and yes I grabbed a copy of annual rpt…reading material for plane trip home!! #ISPORAnnual #heor #hta
0
3
4
Come find me at poster 4012 to discuss @TuftsCEVR SPEC database research on commercial coverage of Accelerated Approval drugs. And grab a copy of our Annual Specialty Drug Coverage Trend Report 2024! #ISPORAnnual #heor #hta
1
6
7
The @TuftsCEVR Spring newsletter is out! Featuring new research in valuing health, how payers are covering cell & gene drugs, and other issues. https://t.co/cJOR69Abh7
#heor #healtheconomics
0
10
11
Congratulations to the Tufts-CEVR team for another successful annual meeting!
0
6
14
Great discussion with @PeterNeumann11 at @TuftsCEVR’s annual meeting, where we covered everything from value-based agreements to the exciting future of brain health. As science evolves, let's prioritize value over cost and work to break access barriers for patients and families.
1
4
20
I have an abstract focused on pharmacy closures for #APPAM2024 and looking for related abstracts to put together a panel. #HealthPolicy abstracts on prescription drugs or geographic access to care could fit well. Let me know if you have a potential abstract @APPAM_DC
2
11
14